Bildkälla: Stockfoto

Gasporox: Executing its long-term strategy - Redeye

Gasporox’s results closely align with RRe expectations, showing seven quarters of positive EBITDA driven by sales from VialArch, GPX1500, and after-sales services. The company is preparing to launch a new version of VialArch in June and is already securing pre-orders from the pharma and beverage sectors. The upcoming debt maturity might pressure the share, while forthcoming earnings and order announcements could boost it.

Gasporox’s results closely align with RRe expectations, showing seven quarters of positive EBITDA driven by sales from VialArch, GPX1500, and after-sales services. The company is preparing to launch a new version of VialArch in June and is already securing pre-orders from the pharma and beverage sectors. The upcoming debt maturity might pressure the share, while forthcoming earnings and order announcements could boost it.
Börsvärldens nyhetsbrev
ANNONSER